Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial

Mosun-Pola demonstrated superior efficacy versus R-GemOx, with significant improvements in both ORR and PFS, and infrequent CRS events with a manageable safety profile.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-10-02
DOI
https://doi.org/10.1200/jco-25-01957
Citations
4
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
5.89
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial

Nikesh Shah, Shen Yin, Martin Janousek, Huilai Zhang et al.
4 citations
Journal of Clinical Oncology
Lymphoma Diagnosis and Treatment
5.89
article

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial

Nikesh Shah, Shen Yin, Martin Janousek, Huilai Zhang, Astrid Pavlovsky, Hideki Goto, Danielle Leão Cordeiro de Farias, Lalita Norasetthada, Jason R. Westin, Young‐Woo Jeon, Bei Hu, Julian Ashby, Dai Maruyama, Eduardo Magalhães Rego, Connie Lee Batlevi, Laura Fogliatto, Adam J. Olszewski, Michael C. Wei, Huangming Hong, Won Seog Kim, Antonia Kwan, Lihua E. Budde, Muhıt Özcan, Wahib S. Ead, Jue Wang, Hao Wu, Song Pham, Iris To
article en
4 citations

Abstract

Mosun-Pola demonstrated superior efficacy versus R-GemOx, with significant improvements in both ORR and PFS, and infrequent CRS events with a manageable safety profile.

Journal of Clinical OncologyVol. 43(36)
Roche (Switzerland) (CH), The University of Texas MD Anderson Cancer Center (US), Ankara University (TR), Brown University (US), Tampa General Hospital (US), Samsung Medical Center (KR), Tianjin Medical University Cancer Institute and Hospital (CN), Roche (Canada) (CA), Hospital de Clínicas de Porto Alegre (BR), Levine Cancer Institute (US), D’Or Institute for Research and Education (BR), The Catholic University of Korea Yeouido St. Mary's Hospital (KR), City of Hope (US), Beneficência Portuguesa de São Paulo (BR), Fundación para la Investigación, Docencia y Prevención del Cáncer (AR), Hokkaido University Hospital (JP), Japanese Foundation For Cancer Research (JP), Chiang Mai University (TH)
Openalex Percentile: Top 4%
Lymphoma Diagnosis and Treatment
5.89
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.